Human Immunology Biosciences

Biotech & Life Sciences · San Francisco, United States · Founded 2021

HI Bio is a clinical-stage biotechnology company focused on developing targeted therapies for patients suffering from severe immune-mediated diseases (IMDs). Leveraging human genetic and immunological insights, HI Bio aims to deliver precision medicine solutions that address the root causes of these complex conditions. The company operates in the biopharmaceutical market, primarily serving healthcare providers and patients who require advanced therapeutic options for immune system dysfunctions. HI Bio's business model revolves around research and development, clinical trials, and eventual commercialization of its proprietary therapies. Revenue is generated through a combination of funding rounds, partnerships, and future sales of approved treatments. The company recently secured $95 million in Series B financing to advance its pipeline of targeted therapies. Keywords: biotechnology, immune-mediated diseases, precision medicine, genetic insights, immunological insights, clinical-stage, targeted therapies, biopharmaceutical, Series B financing, healthcare providers.

Valuation $1–2.5B

Headcount <100

Total funding $100–500M

Unlock exact values

Power Law Unicorn$1–10B valuation tier

Featured in

Market map 600+ Global VC backed Precision Medicine startups

Investors

9 investors on Human Immunology Biosciences's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 6 investors entered at this stage

ARCH Venture Partners

Monograph Capital

Jeito Capital

Alpha Wave Global

Arkin Capital

Viking Global Investors

Series B+ 3 investors entered at this stage

Arkin Capital

Alpha Wave Global

Viking Global Investors

Global footprint

Where Human Immunology Biosciences has talent and traffic

Workforce by country

2 countries with
team presence

🇺🇸 United States93.3%

🇦🇺 Australia6.7%

2 countries shown

Web traffic by country

670 monthly visits
across markets

🇺🇸 United States104.5%

Top 1 markets shown

Talent graph

The shape of Human Immunology Biosciences's talent

Dealroom maps Human Immunology Biosciences's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

16 team members profilednamed & role-tagged by Dealroom

20 employeestotal headcount

1 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Human Immunology Biosciences's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Human Immunology Biosciences

An AI-synthesized read of the highest-engagement posts about Human Immunology Biosciences on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Human Immunology Biosciences on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles